Pharvaris N.V. is a clinical-stage company dedicated to developing and commercializing oral drugs that target crucial biological pathways that are well-suited to address multiple indications. The company's primary focus is on the development of treatments for patients suffering from hereditary angioedema (HAE), a rare genetic disorder affecting roughly 1 in 10,000 to 1 in 50,000 people globally, which causes episodic yet severe swelling attacks.
Pharvaris was founded in 2015 and is registered in the Netherlands. The company deploys an innovative approach to drug development, leveraging its expertise in small molecule drug discovery and development, specifically focusing on Bruton’s tyrosine kinase (BTK) inhibitor design and synthesis. BTK plays a critical role in the onset of swelling in HAE patients, hence the significance of this line of research.
The company's lead program, PHVS416, utilizes this approach and is a technologically advanced oral formulation of PHA121, a potent and selective BTK inhibitor. PHVS416 is designed to provide effective, rapid, and sustained relief from HAE attacks, hence significantly improving the patients' quality of life. Similarly, Pharvaris is advancing another drug candidate, PHVS719, which is also an orally administered BTK inhibitor targeting HAE prophylaxis.
Pharvaris's commitment to developing oral therapies for HAE stems from the understanding that many patients prefer oral medication. Current treatments for HAE primarily involve intravenous or subcutaneous injections, which can be inconvenient and painful for patients. Aside from making treatments more patient-friendly, the development of orally administered drugs for HAE may also serve to expand the treatment market.
Pharvaris expressed its commitment to drug development for HAE treatment and other potential indications by pointing out that small molecule BTK inhibition, in addition to HAE, holds the potential for therapeutic benefit in a broad range of other diseases, and they are dedicated to exploring these possibilities.
Since its establishment, Pharvaris has equipped itself with a team of scientists possessing extensive experience in the pharmaceutical industry, particularly in the area of small molecule drug discovery and development. With a management team that holds a proven track record in the pharmaceutical industry, Pharvaris is well-positioned to fulfill its mission of developing and commercializing new treatments for patients with significant unmet medical needs.
To summarize, Pharvaris is striving to bring about a paradigm shift in the treatment options for hereditary angioedema and potentially other diseases. They continue to leverage their expertise, innovative approach, and dedication to patient-centric solutions to revolutionize care for HAE patients. As a relatively young company with a robust pipeline, Pharvaris is well-positioned for future growth.